Considering its short half-life, endogenous FGF21 is not suitable for clinical application; therefore, long-acting FGF21 analogs have been used in preclinical trials for the treatment of obesity and associated metabolic disorders [11, 14, 15]. The gene discussed is FGF21; the disease is metabolic disease.